The estimated Net Worth of George Uveges is at least $725 Tisíc dollars as of 7 March 2018. George Uveges owns over 35,054 units of Harvard Bioscience stock worth over $461,369 and over the last 19 years George sold HBIO stock worth over $263,504.
George has made over 6 trades of the Harvard Bioscience stock since 2015, according to the Form 4 filled with the SEC. Most recently George sold 35,054 units of HBIO stock worth $161,599 on 7 March 2018.
The largest trade George's ever made was exercising 67,478 units of Harvard Bioscience stock on 7 September 2017 worth over $166,671. On average, George trades about 7,305 units every 31 days since 2006. As of 7 March 2018 George still owns at least 163,028 units of Harvard Bioscience stock.
You can see the complete history of George Uveges stock trades at the bottom of the page.
George's mailing address filed with the SEC is 207 Willow Brook Dr, Wayland, MA 01778, USA.
Over the last 21 years, insiders at Harvard Bioscience have traded over $10,145,146 worth of Harvard Bioscience stock and bought 754,658 units worth $2,380,232 . The most active insiders traders include Earl R Lewis, Bertrand Loy a David Green. On average, Harvard Bioscience executives and independent directors trade stock every 43 days with the average trade being worth of $182,054. The most recent stock trade was executed by James W Green on 13 June 2024, trading 10,000 units of HBIO stock currently worth $29,100.
harvard bioscience is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories worldwide. we sell our products to thousands of researchers in over 100 countries through our full-line catalog (and various other specialty catalogs), our websites, and through distributors, including ge healthcare, thermo fisher scientific inc., and vwr. we have sales and manufacturing operations in the united states, the united kingdom, germany, and spain and sales facilities in france and canada.
Harvard Bioscience executives and other stock owners filed with the SEC include: